---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-146299"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:45:31.513029+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q1 revenue down 4% to $98.1M; net income drops to $0.1M from $9.9M

## Summary
- Net revenue $98.1M, down 4% YoY; adjusted net income $1.2M vs $11.2M.
- Surgical & Sports Medicine revenue fell 39% to $7.2M due to ReNu/NuCel discontinuation.
- PuraPly revenue grew 29% to $53.3M, partially offsetting declines.
- Adjusted EBITDA $5.0M, down 69% from $16.0M; cash at $108.5M.
- FY2022 guidance: net revenue $485M-$515M, net income $41.2M-$52.7M.

## SEC filing metadata
- accession: 0001193125-22-146299
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000119312522146299/0001193125-22-146299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000119312522146299/d332410d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-146299
- JSON: https://secwatch.observer/filing/0001193125-22-146299.json
- Plain text: https://secwatch.observer/filing/0001193125-22-146299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.